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Abstract
Background: Anti-ischemic effects of NO releasing by nitroglycerin (NTG) and the release of calcitonin gene-related
peptide (CGRP) are involved in the decrease of vascular remodeling in different cardiovascular diseases. Using a
nitrate-free period is still generally required to prevent nitrate tolerance and should be used as the first-line option
to maintain adequate symptom control and on an individual basis. Personalized anti-ischemic concerns require the
urgent change of paradigm from interventional measures to predictive, preventive, and personalized treatment
with organic nitrates and its combination with drugs that may improve prognosis and drugs that can be added for
patients who remain symptomatic despite therapy with the other classes of agents. The purpose of this study was
to evaluate the influence of human calcitonin gene-related peptide antagonist (CGRP8-37) on cardiohemodynamic
events, prostaglandin E2 (PGE2) plasma concentration, the severity of ventricular arrhythmias, and mortality
occurring during acute myocardial infarction (AMI) in NTG-tolerant and nontolerant rats.
Methods: In the pilot study of efficacy of calcitonin gene-related peptide antagonist (CGRP8-37), 58 male Wistar rats
were included. All procedures were performed according to protocols approved by the General Animal Care and
Use Committee. Adult male rats underwent surgery to induce AMI by ligating the left anterior descending coronary
artery or SHAM. ECG was used to confirm myocardial ischemia. In each experiment, a rat was maintained under
anesthesia for the duration of the experiment. At the end of the experiment, the rat was killed by an overdose of
pentobarbital. All animals in accordance with the received pharmacological agent were randomized into three
groups: I—received only NTG, 50 mg/kg daily, s.c. injections b.i.d. 3 days prior to AMI; II—received NTG by the same
dose, route, and frequency of administration + CGRP antagonist (CGRP8-37), 10 μg/kg two times daily by a similar
period of administration; and III—served as control (C) group without preliminary tolerance to NTG.
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Results: Subcutaneous injections of NTG (50 mg/kg) 30 min prior to AMI in NTG-tolerant animals (group I)
and in NTG-tolerant rats + CGRP antagonist (group II) caused minor changes in blood pressure and heart
period that was accompanied before NTG s.c. administration with blunted baroreflex sensitivity in response to
i.v. administration of sodium nitroprusside in these groups of rats (0.66 ± 0.05 and 0.56 ± 0.04 ms/mmHg, P <
0.05, respectively) in comparison to C (group III) animals (0.9 ± 0.1 ms/mmHg). AMI 1 h duration was
associated with a high incidence of ventricular arrhythmia and significant mortality in group I (70 %) and
especially in group II (90 %) animals at 72 h after reperfusion as compared with group III rats (56 %), that
correlated to a decrease of PGE2 plasma content in group II (2.2 ± 0.4 ng/ml, P < 0.001) and group I (3.6 ±
0.2 ng/ml, P < 0.01) vs. control group of rats (4.8 ± 0.3 ng/ml).
Conclusions: CGRP could be involved in the mechanism of nitrate tolerance via the inhibition of release of
the potent vasodilator CGRP leading to exacerbation of acute myocardial ischemia. The influence of CGRP
antagonist could enhance this condition.
Keywords: Predictive preventive personalized medicine, Acute myocardial infarction, Nitroglycerine tolerance,
Calcitonin gene-related peptide antagonist, Ventricular arrhythmias, Baroreflex sensitivity, Mortality,
Hemodynamic, Prostaglandin E2
Background
Coronary artery disease (CAD) is the predominant
cause of death in most developed countries. The
clinical challenge in the treatment of angina and
acute coronary syndrome and possibly less of an
issue of chronic ischemic heart disease is the devel-
opment of tolerance to nitrate therapy. No one ther-
apy that has been studied seems convincing as
providing a solution to nitrate tolerance either be-
cause conflicting results have been published or be-
cause data are too limited to make specific
recommendations. Recent pre-clinical and clinical
studies have established that, rather than a homoge-
neous class, organic nitrates represent a heteroge-
neous group of substances that differ greatly with
respect to side effects such as the induction of ni-
trate tolerance and endothelial dysfunction. Further-
more, studies of alternative options to avoid or
manage nitrate tolerance have used hemodynamic
endpoints and not clinical endpoints, so their results
are difficult to translate into clinical practice. Using
a nitrate-free period is still generally required to pre-
vent nitrate tolerance and should be used as the
first-line option to maintain adequate symptom con-
trol and on an individual basis [1]. Thus, personal-
ized anti-ischemic concerns require the urgent
change of paradigm from interventional measures to
predictive, preventive, and personalized treatment
with organic nitrates and its combination with drugs
that may improve prognosis (such as statins, ACE
inhibitors, and aspirin, or, in the secondary preven-
tion, beta-receptor blockers) and drugs that can be
added for patients who remain symptomatic despite
therapy with the other classes of agents (such as cal-
cium antagonists, beta-receptor blockers). Some
experimental and clinical studies have suggested
that long-term nitrate treatment does not improve
or may even worsen cardiovascular mortality, pos-
sibly due to the development of vascular nitrate
tolerance.
The rapid development of tolerance against the
hemodynamic effects of nitrates during sustained ther-
apy limits their clinical application [2–4]. Nitroglycerin,
which helps impaired cardiac function as it is converted
to nitric oxide, is used worldwide to treat patients with
various ischemic and congestive cardiac diseases, including
angina pectoris. The mechanism underlying nitrogly-
cerin-induced vascular smooth muscle relaxation in-
volves NO production, which stimulates both soluble
guanylate cyclase (sGC) and release of prostacyclin or
prostaglandin E (PGE). Activation of sGC and adenylyl
cyclase (AC) increases the formation of the second mes-
sengers cyclic guanosine monophosphate (cGMP) and
cAMP. Subsequent activation of cGMP- and cAMP-
dependent kinase (cGK and cAK) leads to vasorelaxation
by phosphorylation of vasodilator-stimulated phosphopro-
tein (p-VASp) at serine 239 [5–9]. Increased generation of
oxygen free radicals during nitrate therapy may be another
important mechanism of tolerance [7, 10, 11]. Long-term
treatment with NTG stimulates the production of reactive
oxygen species such as peroxynitrite (ONOO−), which
may in turn induce tolerance and endothelial dysfunction
[7, 12–14]. Previous studies have suggested that NTG can
evoke the release of calcitonin gene-related peptide
(CGRP), which is widely distributed in vascular tissues
(and is a potent vasodilator), from capsaicin-sensitive sen-
sory nerves [3]. It was shown that CGRP mediates the de-
pressor effect and vasodilatation produced by NTG via
the cGMP pathways [15, 16]. Recent evidence suggest that
diminished availability of CGRP is associated with nitrate
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tolerance [10, 16]. The mechanisms underlying NTG-
induced vascular smooth muscle relaxation encompassing
sGC pathway and release of vasodilating prostaglandins.
At the same time, the CGRP, which is a potent vasodilator
and mediates the depressor effect and vasodilation, is pro-
duced by NTG via the cGMP pathways. Based on these
biochemical pathways, the CGRP antagonist (human cal-
citonin gene-related peptide antagonist (CGRP8-37)) may
contribute to NTG-induced tolerance, cardiohemody-
namic events, and mortality during myocardial infarction.
Anti-ischemic effects of NO releasing by NTG and the
release of CGRP are involved in the decrease of vascular
remodeling in different cardiovascular diseases. The pur-
pose of this study was to evaluate the influence of the
CGRP (human CGRP8-37, Sigma-Aldrich) antagonist on
cardiohemodynamic events, prostaglandin E2 (PGE2)
plasma concentration, the severity of ventricular ar-
rhythmias (VA), and mortality occurring during acute
myocardial infarction (AMI) in nitroglycerin-tolerant
and nitroglycerin-nontolerant rats.
Methods
In the pilot study of the efficacy of calcitonin gene-
related peptide antagonist (CGRP8-37), 58 male Wistar
rats weighing 250–300 g were included. All animals were
handled in compliance with the European Convention
on Animal Care and received humane care in accord-
ance with the Principles of Laboratory Animal Care and
the Guide for the Care and Use of Laboratory Animals
(published in the Official Daily N. L358/1-358/6, 18
December 1986), and the US National Institutes of
Health (Guide for the Care and Use of Laboratory Ani-
mals, NIH publication no. 85-23) and all procedures
were performed according to protocols approved by the
General Animal Care and Use Committee of the Depart-
ment of Pharmacology of I. Javakhishvili Tbilisi State
University, Department of Medical Pharmacology and
Pharmacotherapeutics of Tbilisi State Medical Univer-
sity, and International Scientific Centre of Introduction
of New Biomedical Technology, Tbilisi, Georgia. Ani-
mals which were maintained and fed ad libitum on the
standard normal-protein diet and had free access to
water were used in the study. They were housed indi-
vidually in a humidity- and temperature-controlled room
with a 12-h light/dark cycle at a temperature of 22 °C.
Adult male rats underwent surgery to induce acute myo-
cardial infarction (AMI) by 40 % ligation of the left an-
terior descending coronary artery or SHAM, and a 72-h
recovery period was given in order to fully evaluate the
mortality rate. ECG tracing in lead II was obtained per-
manently before induction of AMI and up to 60 min
postinfarction to confirm myocardial ischemia. In each
experiment, a rat was maintained under anesthesia dur-
ing experiments. At the end of the experiment, the rat
was killed by an overdose of sodium pentobarbital. Tol-
erance was induced by treatment with NTG (50 mg/kg
daily, s.c. injections b.i.d.) for 3 days and was confirmed
in previous experiments by a reduction in hypotensive
responses and reflex tachycardia to intravenous NTG,
that have been measured by tail-cuff method and cardio-
tachometer, respectively. All animals in accordance with
the received pharmacological agent were randomized
into three groups: I—received only nitroglycerin (NTG,
50 mg/kg daily, s.c. injections b.i.d.) 3 days prior to AMI;
II—received NTG by the same dose, route, and fre-
quency of administration + CGRP antagonist (CGRP8-37,
Sigma-Aldrich), 10 μg/kg two times daily by a similar
period of administration; and III—served as control (C)
group without preliminary tolerance to NTG. After
3 days, the rats were anesthetized with sodium pentobar-
bital (60 mg/kg). A polyethylene catheter was implanted
into the right femoral artery and connected to a blood
pressure transducer for measuring blood pressure (BP)
with an electromanometer and heart period (HP) with a
cardiotachometer. Baroreflex sensitivity (BRS) was
assessed by measuring HP in response to reduction in
BP induced by i.v. sodium nitroprusside 10 μg/kg. There
was a highly significant linear relationship between HP
and BP for each experimental treatment (r values ranged
from 0.84 to 0.98). The slope of relationship between BP
and HP was used as an index of BRS [11]. NTG (50 mg/
kg) s.c. was administered 30 min prior to coronary artery
ligation. At 60 min postinfarction for determination of
PGE2 plasma content, 1 ml of blood was drawn from the
femoral artery and was aliquoted in plastic tubes
(100 μl/tube) and then treated with the Ca2+ ionofore A
23187 (50 μl M) [17]. Fifteen minutes later, the tubes
were centrifuged (1500g, 4 °C, 5 min) and the plasma
obtained was stored (−40 °C) until measurement of
PGE2 were performed using enzyme immunoassay kits
(EIA) (R&D System, Minneapolis, MN).
Results are reported as mean ± standard deviation, and
Student’s t test was used to compare mean values. Statis-
tical differences were considered significant when P <
0.05. Means of the hemodynamic and baroreflex vari-
ables were compared between groups and throughout
protocol by two-way analysis of variance (ANOVA) with
repeated measures.
Results
Mortality after acute myocardial infarction in different
groups of animals
The analysis of lethal outcome during MI showed the
highest incidence of mortality in group I and especially
group II of rats (Table 1). In the case of NTG-tolerant
rats, the lethal outcome reached 70 %, while in group II
of the animals, the mortality was 90 %. Most animals
from the abovementioned groups died during 0–24 h in
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comparison to nontolerant rats in which NTG s.c. injec-
tion partially prevents the development of severe ven-
tricular arrhythmias and decreased incidence of
mortality (56 %) vs. 70 and 90 % in groups I and II of
the animals, respectively, during 0–24 h. Eventually, ac-
cording to our results, it may be suggested that in NTG-
tolerant rats, the vasorelaxation properties of s.c. NTG
is markedly reduced, which is associated with the reduc-
tion of cardiac rhythm compensatory enhancement and
diminution in BRS.
Hemodynamics response and baroreflex sensitivity in
NTG-tolerant rats with acute myocardial infarction
A nitrate tolerance state means that after a prolonged,
continuous, or high-dose nitrate treatment, the clinical
or hemodynamic response to organic nitrates (i.e., vaso-
dilation with subsequent decrease in BP or relief of an-
gina pain) is attenuated or abolished. As shown in
Table 2 in our experiments, s.c. injection of NTG in a
dose of 50 mg/kg 30 min prior to AMI caused a distinct-
ive alteration in hemodynamic parameters of different
groups of rats. The hypotensive reaction was markedly
expressed in nontolerant, control group of animals with a
corresponding decrease in arterial pressure in aver-
age—28.4 ± 2.5 mmHg (P < 0.05). BP reduction in these
animals was accompanied with reflex tachycardia and
diminution in heart period (HP)—25.6 ± 3.8 ms (P < 0.05)
below the control level. Such hemodynamic changes in
nontolerant rats were correlated with markedly expressed
BRS (0.9 ± 0.1 ms/mmHg) with reduction in HP in
response to decreases in BP obtained by sodium nitro-
prusside administration before NTG s.c. injection. In con-
trast to nontolerant rats, s.c. injection of NTG in NTG-
tolerant animals (group I) and in NTG-tolerant rats +
CGRP antagonist caused less decrease in BP and HP
which was combined with blunted BRS (0.66 ± 0.05 and
0.58 ± 0.04 ms/mmHg, P < 0.05 in groups I and II of rats,
respectively) in response to reduction in BP.
Changes in ECG parameters in NTG-tolerant rats with
acute myocardial infarction
The estimation of ECG showed that AMI was accom-
panied by a high incidence of ventricular arrhythmias
(VA) in a form of ventricular tachycardia (VT) and ven-
tricular premature beats (VPBs). Myocardial ischemia in-
duced the elevation of ST segment with its following
inversion, which in majority of groups I and II of rats
unlike control group of animals (Table 3) was associated
with VT in which the duration in NTG-tolerant (19 ± 4 s
(P < 0.001) and especially NTG-tolerant + CGRP antag-
onist rats 24 ± 6 s (P < 0.001) significantly exceeds such
episodes in nontolerant (control group) rats (9 ± 2 s).
The average number of evoking VPBs in each animal of
groups I and II significantly exceed those in the control
group of rats (520 ± 38 and 668 ± 52 vs. 440 ± 30, re-
spectively). The severe arrhythmias in groups I and II of
rats sometimes transformed into ventricular fibrillation
with lethal outcome, while in nontolerant rats, its
episodes were absent.
PGE2 generation in NTG-tolerant rats with acute myocar-
dial infarction
Because one of the markers of adaptive (positive) reserve
of ischemic/hypoxic damage of myocardium is the up-
regulation of COX-2 with a subsequent increment of
PGE2 generation, we have determined the content of
PGE2 as a cytoprotective heart prostanoid in hypoxic
conditions in NTG-tolerant animals after AMI [2]. The
content of PGE2 in blood samples obtained at 60 min of
AMI revealed a great difference in experimental animals
(Fig. 1). Its maximal concentration has been identified in
nontolerant rats (group C) with mean values 4.8 ±
0.3 ng/ml vs. NTG-tolerant (3.6 ± 0.2 ng/ml) and NTG-
Table 1 The influence of NTG on the mortality in NTG-tolerant
rats with acute myocardial infarction
Group of animals Mortality
0–24 h 24–48 h 48–72 h
Control (n = 18) 5 2 3
Total = 10/18 (56 %)
I—NTG-tolerant (n = 20) 11 3 –
Total = 14/20 (70 %)
II—NTG-tolerant + CGRP antagonist (n = 20) 18 – –
Total = 18/20 (90 %)
Note: comparison the same as Table 3
Table 2 The NTG-induced cardiohemodynamic alterations in different groups of rats with acute myocardial infarction
Parameters Animal groups
Control (nontolerant), n = 18 I—NTG-tolerant, n = 20 II—NTG-tolerant + CGRP antagonist, n = 20
a b a b a b
BP (mmHg) 115 ± 6 −28.4 ± 2.5 109 ± 5 −16.2 ± 1.6* 110 ± 8 −8.8 ± 1.2***###
HP (ms) 158 ± 7 −25.6 ± 3.8 151 ± 5 −11.0 ± 1.2* 147 ± 6 5.2 ± 1.4***###
BRS (ms/mmHg) 0.9 ± 0.1 0.66 ± 0.05** 0.58 ± 0.04**
BP blood pressure, HP heart period, BRS baroreflex sensitivity, a initial values, b after NTG injection, n number of animals
Difference with the control group: *p < 0.05; **p < 0.01; ***p < 0.001; difference with the I—NTG-tolerant group: ###p < 0.001
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tolerant + CGRP antagonist (2.2 ± 0.4 ng/ml) groups of
animals, respectively (P < 0.05), that proves the reduction
of PGE2 release in NTG-tolerant and predominantly in
NTG-tolerant + CGRP antagonist group of animals.
PGE2 could act as a beneficial modulator in the myocar-
dium and prevents a major injury of it.
Diminished release of PGE2 and CGRP may be partially
accountable for such alteration because in NTG-tolerant
rats and NTG-tolerant + CGRP antagonist animals, PGE2
blood content is profoundly reduced in comparison to
nontolerant rats. Along with such changes, the cardiopro-
tective properties of s.c. NTG in the case of tolerant con-
dition is significantly reduced, that was proved by more
incidence of severe ventricular arrhythmias and high fre-
quency of mortality in these groups of animals to compare
with nontolerant rats.
Discussion
Tolerance is an important consideration in the use of ni-
trates [18, 19], and NTG therapy has been shown to be
associated with activation of neurohormonal vasocon-
strictor forces. NTG-induced decreases in BP caused baro-
reflex stimulation leading to a variety of neurohumoral
adjustments, which include increases in catecholamine levels
and release rates and increases in plasma vasopressin [16],
plasma renin activity, and angiotensin II and aldosterone
levels [12, 20]. The intrinsic mechanism of angiotensin II
(AngII) and sympathetic nerve reflexes, baroreflex sensitiv-
ity, and sensory nerve activator homeostasis maintenance
includes the sensory nerve-derived CGRP release stimula-
tion. CGRP does not play a primary role in the regulation of
basal blood pressure (BP) in normal individuals but is sug-
gested to have protective properties, in cardiovascular dis-
ease, including attenuation of vascular smooth muscle
proliferation, hyperplasia, and stimulation of endothelial cell
proliferation and endothelial progenitor cells [21]. However,
there is little evidence of detailed analysis involving the on-
going influence of endogenous CGRP on vascular remodel-
ing, especially with regard to NO and oxidative stress
pathways. In our experiments in NTG-tolerant animals and
especially in NTG-tolerant rats + CGRP antagonist, subse-
quent NTG injections 30 min prior to AMI did not cause
significant changes in BP and HP that was accompanied
with a reduction of baroreflex sensitivity in comparison to
control group of rats. These results correspond to the find-
ings of the abovementioned authors, and other investigators
demonstrated that long-term continuous transdermal NTG
therapy has been associated with altered autonomic neural
function, including impaired baroreflex activity and in-
creased sensitivity to receptor-dependent vasoconstrictors
such as serotonin, phenylephrine, angiotensin II, and throm-
boxan [16, 20]. A marked increase in intravascular volume,
secondary to the transvascular shift of fluid and/or to
aldosterone-mediated salt and water retention, has also been
observed in patients treated with NTG. Although these
changes could attenuate the preload effect of NTG, evidence
suggest that these mechanisms are not sufficient to fully
explain the loss of nitrate effectiveness, and the prognostic
implications of these changes, other mechanisms of
tolerance, and hypothesis that explained all these alterations
had to be sought [10, 16]. Evidence of NTG-induced in-
creased reactive oxygen species (ROS) production in
humans was obtained ex vivo in arterial segments and in
blood or platelets taken from patients rendered tolerant to
Table 3 The influence of NTG on arrhythmias in NTG-tolerant rats with acute myocardial infarction
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Control I - NTG-tolerant II - NTG-
Fig. 1 Effect of NTG (50 mg/kg) s.c. 30 min prior to AMI on the blood
content of PGE2 in different groups of rats with myocardial ischemia.
C control group (n = 18), I NTG-tolerant (n = 20), II NTG-tolerant + CGRP
antagonist (n = 20)
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NTG [7, 13, 18, 22, 23]. NTG tolerance was also associated
with increased markers of free radical-induced lipid peroxi-
dation such as cytotoxic aldehydes and isoprostanes [23, 24]
and esterified 8-epi-PGE2α [24] and with a mild reduction in
the responsiveness to the NO donor sodium nitroprusside
in healthy volunteers [15], which might also be compatible
with ROS-mediated interference with NO signaling [16].
From these findings, the authors proposed that the existence
of a unifying hypothesis that founded on the concept of
NTG-induced increased oxidative stress could be compat-
ible with the multiple different observations associated with
long-term nitrate treatment [19, 20]. Existing observations
include the demonstration that the vasodilator actions of
NTG are, at least in part, endothelium-dependent and that
in the presence of increased oxidative stress, NTG can ac-
tively cause constriction of resistance vessels via release of
PGF2α and TXA2 [13, 24, 25]. In our experiments in groups
I and II of the animals, a marked decrease of PGE2 content
in blood samples obtained at 60 min of AMI has been
established in comparison to group III of rats that proves
the reduction of PGE2 release in NTG-tolerant and predom-
inantly in the NTG-tolerant + CGRP antagonist group of
animals. These findings indicated the reduction releases of
vasodilating PGE2 in NTG-tolerant rats. At the same time,
there is controversial data concerning the anti-ischemic
effects of NTG in NTG-tolerant rats [13, 25]. The preferen-
tial effect of nitrates is the dilation of the systemic veins;
however, they also cause arterial vasodilation leading to de-
creased afterload [26–28]. In addition, a direct cardioprotec-
tive effect of nitrate has been implicated [3, 5]. It has been
shown that a non-vasodilator concentration of NTG exerts
a direct myocardial anti-ischemic effect independent of its
vascular actions in isolated rat hearts and in conscious rab-
bits which is not diminished by the development of vascular
tolerance to NTG [4, 29]. However, the involvement of
cGMP in these cardiac effects of nitrates has been ques-
tioned [3]. These studies suggest that the in vivo cellular
mechanisms of action of organic nitrates are probably more
complex than it was previously believed, and it is possible
that nitrates trigger different biochemical mechanisms in the
heart than in the systemic vascular elements [7, 8, 30]. As
an alternative, the mechanism triggered by nitrate treatment
may be the same in the different tissues; however, these
pathways are regulated in a distinct way [26]. Several studies
have demonstrated that despite the loss of preconditioning
induced by rapid ventricular pacing in rabbits that made
them tolerant to the vasodilator effect of NTG, a direct anti-
ischemic effect of NTG was preserved [7, 26, 31–33]. More-
over, neither NTG nor application of preconditioning stim-
uli was effective in increasing cardiac cGMP level in the
tolerant state [10, 34, 35]. It was concluded that NTG might
elicit cardioprotection without involvement of cGMP [29].
Contrary to these findings, clinical studies have suggested
that long-term nitrate treatment does not improve or may
even worsen cardiovascular mortality because nitrate toler-
ance has been shown to increase superoxide and peroxyni-
trate production leading to vascular dysfunction [12, 13, 23,
25, 36, 37]. These data are in accordance with our result-
related hemodynamic events and more high incidence of
VA and mortality in NTG-tolerant rats vs. nontolerant ani-
mals and correlate with findings of previous investigators
that have reported increased expression of endothelin-1 in
endothelial and smooth muscle cells, which in turn stimu-
lates vascular superoxide production, resulting not only in
increased endothelial-1 mediated vasoconstriction but also
in increased formation of peroxynitrate [10]. Previous stud-
ies have suggested that NTG activates capsaicin-sensitive
sensory nerves to release CGRP, which mediates the depres-
sor effect and vasodilation produced by NTG via the cGMP
pathway [14, 38, 39]. It has been demonstrated that the
vasodilator responses and depressor effect of NTG are at-
tenuated or abolished by CGRP antagonist CGRP8-37, or
capsaicin, which selectively depletes CGRP in sensory nerves
[9, 40]. Methylene blue, an inhibitor of soluble guanylate cy-
clase, abolishes the increased release of CGRP produced by
NTG [40]. These findings support the hypothesis that the
cardiovascular effect of nitroglycerin is, at least partially,
mediated by endogenous CGRP via the cGMP pathway
[14, 38]. The development of tolerance to NTG is associated
with the desensitization of mitochondrial ALDH-2 [40],
leading to an attenuated rise in cGMP, and NTG-mediated
CGRP release through the cGMP pathway [14, 40]. These
findings are in agreement with our results that showed the
significant reduction of NTG-induced hemodynamic
changes and BRS in NTG-tolerant rats + CGRP antagonist
with the highest incidence of VA and mortality indicating an
important role of CGRP in the development of NTG-
induced tolerance and NTG effectiveness in AMI.
Conclusions
Our results suggested that NTG tolerance may worsen its
anti-ischemic effect in AMI and cardiovascular mortality,
possibly due to the development of vascular desensitization
involving alteration in CGRP, PGE2 production, and
homeostatic hemodynamic mechanisms. They provide sup-
port for a concept that a stable CGRP agonist may have a
stable preventive and therapeutic potential. The obtained
results gave ground to personalized treatment with nitrates
in various populations; for example, it could be considered
that attenuation of nitric oxide-mediated vasodilation
among blacks as compared to non-blacks is different
throughout racial differences in synthesis and inactivation
of endogenous bioactive nitric oxide.
Recommendations
The therapy with nitrates in patients with cardiovascular
disease requires the development of a personalized algo-
rithm of treatment regime.
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For avoiding the risk of reduction of CGRP releases,
the intermitted regime of nitrate therapy could be
recommended.
In the cohorts of patients with initial diminished levels
of prostaglandin E2, the continuous treatment with ni-
trates could be indicated along with agents improving
endothelial function.
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